RECURRENT MUCOSAL MELANOMA
Clinical trials for RECURRENT MUCOSAL MELANOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT MUCOSAL MELANOMA trials appear
Sign up with your email to follow new studies for RECURRENT MUCOSAL MELANOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Can a newer immunotherapy drug keep melanoma from coming back?
Disease control OngoingThis phase III trial compares the drug pembrolizumab (MK-3475) to the current standard treatments—high-dose interferon or ipilimumab—in 1,301 patients with high-risk melanoma that has been surgically removed. The goal is to see if pembrolizumab is better at preventing the cancer …
Matched conditions: RECURRENT MUCOSAL MELANOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New drug cocktail aims to prevent rare melanoma recurrence
Disease control OngoingThis phase II trial tests whether adding cabozantinib to the immunotherapy drug nivolumab can prevent mucosal melanoma from returning after surgery. About 101 patients with resected mucosal melanoma will receive either nivolumab alone or nivolumab plus cabozantinib. The study aim…
Matched conditions: RECURRENT MUCOSAL MELANOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC